Profile data is unavailable for this security.
About the company
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD1.93m
- Incorporated2024
- Employees--
- LocationCitius Oncology Inc420 Lexington Ave, Suite 2446NEW YORK 10017United StatesUSA
- Phone+1 (347) 627-0058
- Fax+1 (302) 531-3150
- Websitehttps://www.tenxkeane.com/
More ▼
Mergers & acquisitions
| Acquired company | CTOR:NAQ since announced | Transaction value |
|---|---|---|
| Citius Oncology Inc | -83.21% | 675.00m |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | 0.00 | -86.76m | 105.91m | 20.00 | -- | 1.72 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 105.99m | 54.00 | -- | 1.61 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 78.00k | -42.47m | 108.49m | 23.00 | -- | -- | -- | 1,390.94 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -171.44m | 109.03m | 74.00 | -- | 0.6815 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Annovis Bio Inc | 0.00 | -43.02m | 110.57m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 111.98m | 4.00 | -- | 5.14 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 114.09m | -- | 6.61 | 0.2309 | 59.00 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| INmune Bio Inc | 85.00k | -37.74m | 115.74m | 11.00 | -- | 2.77 | -- | 1,361.65 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Verastem Inc | 10.00m | -89.49m | 115.90m | 73.00 | -- | 4.11 | -- | 11.59 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.47m | 116.03m | 10.00 | -- | -- | -- | -- | -0.939 | -0.939 | 0.00 | -0.073 | 0.00 | -- | -- | 0.00 | -171.13 | -- | -333.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 117.51m | 246.00 | -- | -- | -- | 0.3814 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 117.82m | 25.00 | -- | 3.81 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 119.13m | 93.00 | 8.25 | 1.26 | 6.60 | 211.60 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Regulus Therapeutics Inc | 0.00 | -35.39m | 119.15m | 31.00 | -- | 1.21 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Nuvectis Pharma Inc | 0.00 | -21.10m | 121.24m | 13.00 | -- | 9.73 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to Citius Oncology Inc's reporting currency: US Dollar USD
56.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| TD Securities (USA) LLCas of 30 Jun 2024 | 627.18k | 9.43% |
| W.R. Berkley Corp. (Investment Portfolio)as of 31 Mar 2024 | 530.30k | 7.97% |
| Wolverine Asset Management LLCas of 30 Jun 2024 | 407.33k | 6.12% |
| First Trust Capital Management LPas of 31 Mar 2024 | 373.81k | 5.62% |
| RiverNorth Capital Management LLCas of 31 Mar 2024 | 350.00k | 5.26% |
| Mizuho Securities USA LLCas of 30 Jun 2024 | 343.50k | 5.16% |
| Glazer Capital LLCas of 31 Mar 2024 | 311.29k | 4.68% |
| Westchester Capital Management LLCas of 31 Mar 2024 | 300.00k | 4.51% |
| Hudson Bay Capital Management LPas of 31 Mar 2024 | 299.30k | 4.50% |
| Yakira Capital Management, Inc.as of 31 Mar 2024 | 225.00k | 3.38% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
